Novo Nordisk settles Prandin antitrust suit for $19M; Generics maker Oxford Pharma plots new U.S. facility;

@FiercePharma: Ranbaxy fights FDA for killing its approval to make generic Nexium. FiercePharmaManufacturing story | Follow @FiercePharma

@CarlyHFierce: AirFluSal Forspiro won approval in my two favorite countries, Ireland & Czech Republic, which is inconsequential to me but fun nonetheless. | Follow @CarlyHFierce

> Novo Nordisk ($NVO) agreed to pay $19 million to settle a potential class-action suit in the U.S., which claimed the company used "sham" patent litigation to keep a hold on its market for the diabetes drug Prandin. Report

> A generics start-up based in Oxford, England, Oxford Pharmaceuticals, plans to set up a $29 million U.S. facility in Birmingham, AL, that will eventually employ 200 people. Report

> As Allergan's stock rises at the prospect of an Actavis buyout, that offer is growing in value. Report

> Cipla Chairman Yusuf Hamied is grooming his niece and nephew as potential successors to the Indian company's top executives. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Brain tumor treatment device gets early trial halt for efficacy as a combo with chemo. Story | Follow @FierceMedDev

@EmilyWFierce: Shaq is back for $SNY's latest marketing campaign. Release | Follow @EmilyWFierce

> St. Jude's CardioMEMS could help hospitals avoid Affordable Care Act readmission penalties. More

> Baird Capital closes $185M technology, healthcare fund. Item

> Alfred Mann's Second Sight prices $32M IPO for 'bionic eye.' Story

Biotech News

@FierceBiotech: Agios offers another glimpse of 'exciting' early data for a leukemia drug. Report | Follow @FierceBiotech

@JohnCFierce: Lots of discussion about this one -- Average cost of drug R&D? Try $2.9B on for size. Editor's Corner | Follow @JohnCFierce

@DamianFierce: Knight Therapeutics found a buyer for its FDA priority review voucher, selling it to $GILD for $125M. Release | Follow @DamianFierce

> Sanofi's shortlist of CEO candidates so far has a distinct French accent. Item

> Shire orders 500 staffers to move to Boston-area biotech 'Mecca.' Report

> Bind heralds hope for its nanotech cancer drug after mixed Phase II. Story

> Go-go execs at Gilead nab an FDA priority review voucher for $125M. News

Drug Delivery News

> Cynapsus releases clinical trial data about its sublingual thin-film strip for Parkinson's. Item

> Catalent buys particle engineering outfit Micron Technologies. News

> RNAi masking technique allows more efficient delivery. Story

> Medical marijuana company licenses RapidMist device for buccal delivery. Report

> NSF funds further research into only FDA-cleared catheter for rectal delivery. Article

Diagnostics News

> Precision Therapeutics ropes in $60M for corporate overhaul. More

> Cepheid snags $3.3M to roll out rapid Ebola test. Report

> Roche nabs FDA clearance for quick strep test. News

> Illumina, Sequenta partner up on next-gen cancer diagnostic. Article

> Enterome teams up with AbbVie to create molecular Dx for Crohn's disease. Item

Pharma Marketing News

> Payers' hep C delay tactics work: Coverage hurdles may be dampening Harvoni script growth. Article

> How to prep for a 'megablockbuster' launch? Novartis lines up cost-savings data. Report

> Valeant and Allergan's wining-and-dining shows docs still hold the script reins. More

> Painkiller marketing secrets? Check Chicago's unredacted suit against Endo, Purdue, Cephalon, et al. Story

> Sanofi tags newly OK'd MS drug Lemtrada at $158K, ready to tout head-to-head Rebif data. Article

And Finally... Organized crime in Ireland is moving into the counterfeit pharmaceuticals business. Report

Suggested Articles

AZ's tremelimumab has so far suffered a host of clinical failures. But new trial results show the company might be able to use the drug in a new way.

Roche may have just grabbed the first FDA nod for a checkpoint med in previously untreated liver cancer, but Merck is hoping it won’t be far behind.

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.